What People Think
 |
 |
37% For, 63% Against
Take Action
| Vote on this Bill | |
  |
For |
  |
Against |
| Speak Out | |
  |
Comment on this Bill |
  |
Alert Your Friends and Colleagues |
  |
Write Your Representative in Congress |
| Save & Share | |
 |
del.icio.us |
 |
Digg |
 |
|
 |
|
 |
|
 |
Yahoo! |
H.R. 1038, To amend the Public Health Service Act to provide for the licensing of comparable and interchangeable biological products, and for other purposes
Revision History 
Below is the revision history of this article.
(Learn how to edit the WashingtonWatch.com wiki.)
No revisions found.
Learn More
Trackback URL: http://www.washingtonwatch.com/bills/trackback/110_HR_1038.html
RSS Feeds for This Bill
Keep yourself updated on user contributions and debates about this bill! (Learn more about RSS.)
Visitor Comments
HotRod Quarterhorses
It is irresponsible NOT to have a pathway for the review of follow-on biologics. The big drug companies who actually care about patients, like Novartis, are not scared of competition and support this bill. A pathway, without roadblocks, should be implemented asap for patients sake. And the FDA should be given the authority to decide what trials/tests are necessary. That is the FDA's job! Not Congress. Unfortunatly, this debate has exposed the truth behind some of the big pharm's - they care about profit over patients.
Mark McGuigan
Please support this bill as it will serve to start the process of reducing ever-rising drug prices and give access to more individuals for treatment.